Articles

O.10 THE DEUBIQUITINASE USP13 AS A NOVEL THERAPEUTIC CO-TARGET IN EGFR MUTANT NON-SMALL CELL LUNG CANCER

BJMO - 12, issue 3, february 2018

P. Giron , C. Eggermont , E. Teugels PhD, G. Gutierrez , J. De Grève MD, PhD

Read more

P.01 A LUNG CANCER-DERIVED CRAF MUTATION IS ERK PATHWAY ACTIVATING AND PREDICTS SENSITIVITY TO COMBINED TYPE II RAF AND MEK INHIBITION

BJMO - 12, issue 3, february 2018

A. Noeparast PhD, J. De Grève MD, PhD, S. De Brakeleer PhD, P. Giron , C. Eggermont , Rajendra Bahadur Shahi , E. Teugels PhD

Read more

O.04 Type II RAF inhibition causes superior ERK suppression compared to type I RAF inhibition in different BRAF mutant types recurrently found in lung cancer

BJMO - 2017, issue 3, february 2017

A. Noeparast PhD, P. Giron , S. De Brakeleer PhD, U. De Ridder , E. Teugels PhD, J. De Grève MD, PhD

Read more

O.10 USP13 as a novel co-target for EGFR targeted therapies in EGFR mutant non-small cell lung cancer

BJMO - 2017, issue 3, february 2017

P. Giron , C. Eggermont , E. Teugels PhD, G. Gutierrez , J. De Grève MD, PhD

Read more
X